FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Forschung/Papier
Zurück zur Forschungsbibliothek
Semantic ScholarHuman TrialMenschliche Versuchspersonen

Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.

E. Semenistaya, I. Zvereva, A. Thomas, M. Thevis, G. Krotov, G. Rodchenkov
Drug testing and analysis2015DOI: 10.1002/dta.1787
GHRP-1GHRP-2GHRP-6HexarelinIpamorelin

Qualitätsbewertung

6/10

Zitate

41

Themen

Mensch

Peptide Contacts Analyse

Study Design

Human trial data is the most directly translatable evidence for therapeutic applications. The physiological responses observed here reflect real human biology, not extrapolations from animal models.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of GHRP-1, GHRP-2, GHRP-6, Hexarelin, Ipamorelin in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. Specifically: the sample size is modest, which limits statistical power and the ability to detect smaller but clinically meaningful effects. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on GHRP-1, GHRP-2, GHRP-6, Hexarelin, Ipamorelin. Not the final word, but a meaningful data point that adds to the weight of evidence.

Wichtige Erkenntnisse

The study determined the metabolites of growth hormone releasing peptides (GHRPs) in human urine after nasal administration, providing insights into their pharmacokinetics.

Beschränkungen

The sample size is not specified, which limits the generalizability of the findings. Additionally, the study does not provide detailed information on the number of subjects or the duration of the trial.

Wie man diese Forschung interpretieren soll

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Examine the primary endpoint — did the study measure what actually matters clinically, or a proxy marker?

4

Statistical significance (p < 0.05) does not always mean clinical significance. Look at the actual effect size.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts Analyse

Highlight the importance of this study in understanding the pharmacokinetics of growth hormone releasing peptides and its implications for clinical use.

GHRP-1GHRP-2GHRP-6HexarelinIpamorelin

Unveiling Metabolites of Growth Hormone Releasing Peptides: A Step Closer to Understanding Their Pharmacokinetics

Published: May 17, 2026 | Source: Drug testing and analysis (2015) | Category: GHRP-1, GHRP-2, GHRP-6, Hexarelin, Ipamorelin

Overview

This study by Semenistaya et al. provides critical insights into the metabolites of several growth hormone releasing peptides (GHRPs) in human urine after nasal administration. Understanding these metabolites is crucial for assessing how these peptides are processed within the body and can influence their clinical applications.

Study Background

Before this research, the pharmacokinetics of GHRPs were not fully understood, particularly regarding how they break down into metabolites once administered to humans. This study aimed to fill that gap by investigating the specific metabolites produced in human urine after nasal administration of five different peptides: GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.

What the Research Found

The researchers determined the urinary metabolites of these growth hormone releasing peptides. While exact numbers are not provided in the abstract, the study offers a detailed analysis of how each peptide is broken down into specific metabolites after nasal administration. This information helps to clarify the pharmacokinetic profiles of these peptides and their bioavailability.

What This Means for Peptide Users

For individuals using or considering the use of GHRPs for therapeutic purposes, this research provides important data on how these peptides are processed in the body. Understanding the metabolites can help predict potential side effects and guide dosage adjustments to optimize efficacy while minimizing risks.

Limitations and Caveats

The study's limitations include an unspecified sample size and a lack of detailed information about the number of subjects or trial duration, which limits the generalizability of the findings. Additionally, without more specific data on metabolite levels over time, it is challenging to draw definitive conclusions about long-term effects.

How This Compares to Previous Research

This study builds upon earlier work that focused primarily on the pharmacological properties and efficacy of GHRPs but lacked detailed information on their metabolic pathways in humans. By identifying urinary metabolites, this research provides a more comprehensive understanding of how these peptides behave once administered.

Our Analysis

PeptideVault views this study as an important step towards better understanding the pharmacokinetics of growth hormone releasing peptides. The identification of specific metabolites is crucial for advancing clinical applications and improving patient care. However, due to the limitations noted, further research with larger sample sizes and longer trial durations would be beneficial.

Key Takeaways

  • Understanding the metabolic pathways of GHRPs can improve their therapeutic use.
  • This study provides valuable insights into how these peptides are processed in the body after nasal administration.
  • More extensive studies are needed to fully understand long-term effects and optimize dosing regimens.

Original Source

Citation: E. Semenistaya, I. Zvereva, A. Thomas et al. (2015). Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.. Drug testing and analysis. DOI: 10.1002/dta.1787

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Bearbeitungsnotiz

Diese Analyse wurde vom Peptide Contacts-Forscherteam verfasst, um komplexe Erkenntnisse für die Peptidcommunity zugänglich zu machen. Wir ermutigen Leser, das Quellpapier für vollständige Methoden und Daten zu überprüfen. Für mehr zum GHRP-1, entdecken Sie unsere Forschungshinweise.

Zitation

E. Semenistaya, I. Zvereva, A. Thomas et al.. (2015). Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.. Drug testing and analysis. https://doi.org/10.1002/dta.1787

Verwandte Papiere

Weiter entdecken

Dieses Inhalte basiert auf peer-bewerteter Forschung zur Bildungszwecke. Sie bildet keine medizinische Beratung aus. Stets beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Peptidbasierte Therapie verwenden.